ITI-007

Phase 3

Intra-Cellular Therapies, Inc. (ITCI)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

10 competitors in Schizophrenia

TEVArisperidone

JNJpaliperidone ER Oros

Drug Information

Target Indication

Schizophrenia

Clinical Trial

NCT02469155

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ITCI

Intra-Cellular Therapies, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

Lumateperone low dosePhase 3

Irritability Associated With Autism Spectrum Disorder

ITI-007 (Lumateperone)Phase 3

Bipolar Depression

Lumateperone high dosePhase 3

Irritability Associated With Autism Spectrum Disorder

LumateperonePhase 3

Major Depressive Disorder

Lumateperone 42 mgPhase 3

Schizophrenia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts